You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BTK mutation

Showing 1 - 25 of 2,733
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • B-Cell Lymphoproliferative Disorder
  • Boston, Massachusetts
  • +2 more
Feb 18, 2023

Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)

Completed
  • Leukemia, Lymphocytic, Chronic
  • Dresden, Germany
  • +10 more
Jan 13, 2023

B-Cell Malignancies Trial in Canton, Houston (TT-01488)

Recruiting
  • B-Cell Malignancies
  • Canton, Ohio
  • +1 more
Jun 8, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Duarte, California
  • +10 more
Jul 14, 2022

Chronic Lymphocytic Leukemia Trial in Germany (Obinutuzumab, Venetoclax, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Bad Saarow, Germany
  • +29 more
May 4, 2022

Waldenström's Macroglobulinemia Trial in Worldwide (BGB-3111, Ibrutinib)

Completed
  • Waldenström's Macroglobulinemia
  • Phoenix, Arizona
  • +79 more
Jul 6, 2022

Mantle Cell Lymphoma Recurrent Trial in Melbourne (ibrutinib and Tisagenlecleucel)

Active, not recruiting
  • Mantle Cell Lymphoma Recurrent
  • ibrutinib and Tisagenlecleucel
  • Melbourne, Victoria, Australia
    Peter Mac Callum Cancer Centre
Nov 4, 2022

Relapsed/Refractory B-Cell Malignancies Trial in Australia, China (HSK29116)

Recruiting
  • Relapsed/Refractory B-Cell Malignancies
  • Perth, Australia
  • +7 more
Aug 1, 2022

Waldenstrom Macroglobulinemia Trial (Zanubrutinib)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • (no location specified)
Nov 28, 2022

Monoclonal Gammopathy of Uncertain Significance Trial in Utrecht (Zanubrutinib Oral Product)

Not yet recruiting
  • Monoclonal Gammopathy of Uncertain Significance
  • Zanubrutinib Oral Product
  • Utrecht, Netherlands
    University Medical Center Utrecht
Jul 6, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
Mar 16, 2022

CLL/SLL Trial (lisaftoclax +BTK inhibitor, BTK inhibitor)

Not yet recruiting
  • CLL/SLL
  • lisaftoclax +BTK inhibitor
  • BTK inhibitor
  • (no location specified)
Oct 26, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 13, 2022

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Chronic Lymphocytic Leukemia, Loss of Chromosome 17p Trial (Ibrutinib, Venetoclax)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • Loss of Chromosome 17p
  • (no location specified)
Oct 29, 2021

Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 20, 2022

Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
Apr 1, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Mature B Cell Tumors Trial in Tianjin (SHR1459)

Active, not recruiting
  • Mature B Cell Neoplasms
  • Tianjin, Tianjin, China
    Blood disease hospital of Chinese Academy of Medical Sciences
Nov 10, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Zhengzhou, Nanjing (TQB3909 tablet)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • TQB3909 tablet
  • Zhengzhou, Henan, China
  • +1 more
Jul 17, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

The Cre8™ BTK Post Market Clinical Follow-up Study

Not yet recruiting
  • Peripheral Arterial Disease
  • Cre8™ BTK
  • Abano Terme, Padova, Italy
  • +1 more
Nov 8, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Atrial Fibrillation Trial in Caen (Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®))

Not yet recruiting
  • Atrial Fibrillation
  • Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
  • Caen, Normandie, France
    Caen University Hospital, Department of Pharmacology
Sep 6, 2023